Peter Bains
Chief Executive Officer at BIOCON LIMITED
Net worth: 231 114 $ as of 2024-03-30
Profile
Peter James Jonathan Bains is currently the Group Chief Executive Officer at Biocon Ltd.
He is also the Non-Executive Chairman at ILC Therapeutics Ltd.
In addition, he holds the position of Independent Non-Executive Director at Indivior PLC and Director at Sosei R&D Ltd.
Furthermore, he serves as the Chief Business Officer & Non-Executive Director at MiNA Therapeutics Ltd.
and Director at Mina (Holdings) Ltd.
He is also a Non-Executive Director at Apterna Ltd.
In his former roles, Mr. Bains served as the President, Chief Executive Officer & Director at Nxera Pharma Co., Ltd.
from 2016 to 2018.
He was also the Non-Executive Chairman at Fermenta Biotech Ltd.
from 2010 to 2018.
Additionally, he held positions such as Non-Executive Director at Phase4 Partners Ltd., GlaxoSmithKline Pharmaceuticals Ltd., Syngene International Ltd., and Kromek Group Plc.
He was also a Director at Nxera Pharma UK Ltd.
and SmithKline Beecham Ltd.
Furthermore, he worked as the Director at Baines Peter Consulting.
From 2015 to 2021, he served as an Independent Non-Executive Director at Mereo BioPharma Group Plc.
He also held the position of SVP-International Commercial Development at GSK Plc.
Mr. Bains completed his undergraduate degree from The University of Sheffield in 1979.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
INDIVIOR PLC
0.01% | 2024-02-29 | 10,800 ( 0.01% ) | 231 114 $ | 2024-03-30 |
Peter Bains active positions
| Companies | Position | Start |
|---|---|---|
| INDIVIOR PLC | Director/Board Member | 2019-07-31 |
| BIOCON LIMITED | Chief Executive Officer | 2023-09-17 |
| Apterna Ltd. | Director/Board Member | - |
Mina (Holdings) Ltd.
 Mina (Holdings) Ltd. Financial ConglomeratesFinance Mina (Holdings) Ltd. is an investment holding British company founded in 2014. The private company is based in London, UK. The company's main function is to hold investments. | Director/Board Member | 2014-12-16 |
Sosei R&D Ltd.
 Sosei R&D Ltd. Pharmaceuticals: MajorHealth Technology Sosei R&D Ltd. manufactures pharmaceutical products. It develops and commercializes product opportunities based upon clinical uses for known drugs and templates. The company was founded by Julian Gilbert and Robin Bannister in March, 2000 and is located in Saffron Walden, the United Kingdom. | Director/Board Member | 2016-11-30 |
MiNA Therapeutics Ltd.
 MiNA Therapeutics Ltd. BiotechnologyHealth Technology MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom. | Director/Board Member | - |
ILC Therapeutics Ltd.
 ILC Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services ILC Therapeutics Ltd. is a British biotechnology company that conducts research and experimental development. The company is based in Lanarkshire, UK. The company was founded by William H. Stimson. Alan Keith Walker has been the CEO of the company since 2020. | Chairman | - |
Former positions of Peter Bains
| Companies | Position | End |
|---|---|---|
Phase4 Partners Ltd.
 Phase4 Partners Ltd. Investment ManagersFinance Phase4 Ventures ltd (Phase4 Ventures) is a venture capital subsidiary of Nomura International Plc founded in 1999. The firm is headquartered in London, UK. | Director/Board Member | 2022-02-27 |
| MEREO BIOPHARMA GROUP PLC | Director/Board Member | 2021-09-19 |
| ░░░░░ ░░░░░░ ░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░ ░░░░ ░░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Training of Peter Bains
| The University of Sheffield | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 8 |
|---|---|
| INDIVIOR PLC | Health Technology |
| GSK PLC | Health Technology |
| GLAXOSMITHKLINE PHARMACEUTICALS LIMITED | Health Technology |
| BIOCON LIMITED | Health Technology |
| SYNGENE INTERNATIONAL LIMITED | Commercial Services |
| KROMEK GROUP PLC | Health Technology |
| NXERA PHARMA CO., LTD. | Health Technology |
| MEREO BIOPHARMA GROUP PLC | Health Technology |
| Private companies | 10 |
|---|---|
Phase4 Partners Ltd.
Phase4 Partners Ltd. Investment ManagersFinance Phase4 Ventures ltd (Phase4 Ventures) is a venture capital subsidiary of Nomura International Plc founded in 1999. The firm is headquartered in London, UK. | Finance |
Sosei R&D Ltd.
Sosei R&D Ltd. Pharmaceuticals: MajorHealth Technology Sosei R&D Ltd. manufactures pharmaceutical products. It develops and commercializes product opportunities based upon clinical uses for known drugs and templates. The company was founded by Julian Gilbert and Robin Bannister in March, 2000 and is located in Saffron Walden, the United Kingdom. | Health Technology |
Fermenta Biotech Ltd. /Old/
 Fermenta Biotech Ltd. /Old/ BiotechnologyHealth Technology Fermenta Biotech Ltd. manufactures biological products. It supplies Vitamin D3, cholecalciferol also know as Vitamin D3 for further applications in global pharmaceutical, food, veterinary and feed industries (premix), cholecalciferol solutions for use in human food supplements, Vitamin D3 resin in oil and Vitamin D3 500 feed grade for use in animal feed supplements and activated dimethicone powder (Silicon Powder) for antiflatulent use. The company was founded in 1986 and is headquartered in Thane, India. | Health Technology |
Heptares Therapeutics Ltd.
 Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Health Technology |
SmithKline Beecham Ltd.
 SmithKline Beecham Ltd. Pharmaceuticals: MajorHealth Technology Smithkline Beecham Ltd. manufacture of basic pharmaceutical products. It also provides mineral water, bottled water, and soft drinks. The company was founded on January 24, 1989 and is headquartered in Brentford, the United Kingdom. | Health Technology |
| Baines Peter Consulting | |
Mina (Holdings) Ltd.
Mina (Holdings) Ltd. Financial ConglomeratesFinance Mina (Holdings) Ltd. is an investment holding British company founded in 2014. The private company is based in London, UK. The company's main function is to hold investments. | Finance |
ILC Therapeutics Ltd.
ILC Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services ILC Therapeutics Ltd. is a British biotechnology company that conducts research and experimental development. The company is based in Lanarkshire, UK. The company was founded by William H. Stimson. Alan Keith Walker has been the CEO of the company since 2020. | Commercial Services |
| Apterna Ltd. | |
MiNA Therapeutics Ltd.
MiNA Therapeutics Ltd. BiotechnologyHealth Technology MiNA Therapeutics Ltd. develops RNA activation therapeutics. The firm's saRNA platform enables the development of new medicines that restore normal function to patients? cells. It applies technology and clinical know-how to transform the therapy landscape of cancer and other severe diseases. The company was founded by John J. Rossi, Nagy Habib and Pal Saetrom in 2008 and is headquartered in London, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Peter Bains
